Eligo Bioscience, a Paris-based gene-editing company, has raised $30 million in a Series B funding round, marking a significant advancement in the field of genetic medicines. The funding round was led by Sanofi Ventures, with contributions from new investor Bpifrance (through its InnoBio 2 fund) and existing backers Khosla Ventures